A dynamic and comprehensive qualification for you to update your knowledge of the latest developments in blood-borne diseases in a 100% online format” 

Highly aggressive blood-borne pathogens can cause serious consequences for the patient's health. These contagions occur when a healthy person comes into direct contact with the blood and/or body fluids of an infected person. Among the most common are Hepatitis (B and C), HIV/AIDS and Tuberculosis, three diseases that, in just two decades, have caused millions of deaths worldwide. However, continuous research in infectious diseases and medicine has established increasingly effective therapeutic guidelines and prevention strategies to clinically treat these infections. 

In light of this, TECH has designed a novel and intensive program that precisely gathers all the latest developments in a 475-hour academic experience. The result is this Postgraduate Diploma in Blood-Borne Diseases in Clinical Practice, a dynamic and comprehensive course for physicians to delve into the advances in the epidemiology of infectious diseases, guidelines for multi-resistance, the latest vaccines and arbovirosis. It will also focus on the benefits of administering certain treatments and the recommendations for each case.

Over six months, our students will have unlimited access to the best theoretical, practical and additional content, designed by a teaching team versed in the subject that will also be at their absolute disposal to guide them throughout the program and resolve any of their doubts. So, through a 100% online academic experience at the forefront of the medical field, our students will be sure to update their knowledge from wherever they want, without schedules or face-to-face classes, and from any device with an Internet connection. 

You will work intensively on updating your knowledge over 475 hours of the best theoretical, practical and additional material” 

This Postgraduate Diploma in Blood Borne Diseases in Clinical Practice contains the most complete and up-to-date scientific program on the market. The most important features include:

• Case studies presented by experts in infectious diseases in clinical practice 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice 
• Practical exercises where self-assessment can be used to improve learning 
• Its special emphasis on innovative methodologies  
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 

If you are looking for a program that will bring you up to date with the latest developments in Hepatitis, HIV and Tuberculosis in a dynamic and exhaustive way in only six months”   

The program’s teaching staff includes professionals from the sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities.  

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive education programmed to learn in real situations.  

This program is designed around Problem-Based Learning, whereby students must try to solve the different professional practice situations that arise during the academic year. To that end, they will be assisted by an innovative, interactive video system created by renowned and experienced experts. 

You will have unlimited access to the Virtual Campus where all the content will be hosted from the beginning of the academic program"

The best program in the current academic landscape to update your skills in multi-resistance and vaccine use"

TECH developed this Postgraduate Diploma using the Relearning methodology, which consists mainly in the reiteration of the most important concepts, favoring a progressive and natural knowledge update. This pedagogical strategy also guarantees information retention in memory for a longer period of time, without the need to invest extra hours in studying. Thus, this university guarantees a state-of-the-art academic experience, thanks to which our students will not only save time, but will also obtain the best guaranteed results. 

You will find dozens of hours of diverse additional material on the Virtual Campus so you can personally delve into the various sections in the syllabus”  

Module 1. Epidemiology of Infectious Diseases 

1.1. Epidemiological, Economic and Social Conditions by Continent that Favor the Emergence of Infectious Diseases 

1.1.1. Africa 
1.1.2. America 
1.1.3. Europe and Asia 

1.2. New and Emerging Diseases by Continent 

1.2.1. Morbidity and Mortality from Infectious Diseases in Africa 
1.2.2. Morbidity and Mortality from Infectious Diseases in the Americas 
1.2.3. Morbidity and Mortality from Infectious Disease in Asia 
1.2.4. Morbidity and Mortality from Infectious Diseases in Europe 

1.3. The Taxonomy of Infectious Agents 

1.3.1. Viruses 
1.3.2. Bacteria 
1.3.3. Fungi 
1.3.4. Parasites 

1.4. Properties in Microorganisms that Cause Disease 

1.4.1. Pathogenic Mechanisms 
1.4.2. Adhesion and Multiplication Mechanisms 
1.4.3. Mechanisms that Enable Nutrient Acquisition from Hosts 
1.4.4. Mechanisms that Inhibit Phagocytic Processes 
1.4.5. Mechanisms that Circumvent Immune Responses 

1.5. Microscopy and Staining 

1.5.1. Microscopes and Types of Microscopes 
1.5.2. Composite Stains 
1.5.3. Acid-Fast Microorganism Stains 
1.5.4. Stains for Cellular Structures 

1.6. Microorganism Cultures and Growth 

1.6.1. General Culture Methods 
1.6.2. Specific Culture Methods 

1.7. Effect of Chemical and Physical Agents on Microorganisms 

1.7.1. Sterilisation and Disinfection 
1.7.2. Disinfectants and Antiseptics Used in Practice 

1.8. Molecular Biology and Its Relevance to Infectious Disease Specialists 

1.8.1. Bacterial Genetics 
1.8.2. Polymerase Chain Reaction Tests 

1.9. Indication and Interpretation of Microbiological Studies 

Module 2. Occupational Accidents and Blood-Borne Pathogens 

2.1. Epidemiology of Blood-Borne Pathogen Infections 
2.2. Main Blood-Borne Infections 

2.2.1. Hepatitis B Virus Infection 
2.2.2. Hepatitis C Virus Infection 
2.2.3. HIV/AIDS 

2.3. Diagnostic and Therapeutic Approach to Accidents Involving Blood 

2.3.1. Diagnostic Case Monitoring 
2.3.2. Treatment 

2.4. Universal Precautions in the Prevention of Accidents in the Workplace 
2.5. Biosafety Measures and the Role of the Epidemiologist in Reducing Biohazards 

2.5.1. Biological Risk 
2.5.2. Biosafety 

Module 3. Hepatitis and HIV/AIDS and Tuberculosis Co-Infection 

3.1. Viral Hepatitis A 

3.1.1. Virus Characteristics and Replication Cycle 
3.1.2. Clinical Picture 
3.1.3. Viral Markers 
3.1.4. Evolution and Prognosis 
3.1.5. Treatment 

3.2. Viral Hepatitis B and C 

3.2.1. Virus Characteristics and Replication Cycle 
3.2.2. Clinical Picture 
3.2.3. Viral Markers 
3.2.4. Evolution and Prognosis 
3.2.5. Treatment 

3.3. Viral Hepatitis D and E 

3.3.1. Virus Characteristics and Replication Cycle 
3.3.2. Clinical Picture 
3.3.3. Viral Markers 
3.3.4. Evolution and Prognosis 
3.3.5. Treatment 

3.4. Epidemiology of Morbidity and Mortality from TB/HIV/AIDS Co-Infection 

3.4.1. Incidence 
3.4.2. Prevalence 
3.4.3. Mortality 

3.5. Pathobiology from TB/HIV/AIDS Co-Infection 

3.5.1. Pathophysiological Alterations in Co-Infection 
3.5.2. Pathological Alterations 

3.6. Clinical Manifestations of Co-Infection 

3.6.1. Clinical Manifestations of Pulmonary TB 
3.6.2. Clinical Manifestations of Extrapulmonary TB 

3.7. TB Diagnosis in Patients Living with HIV/AIDS 

3.7.1. Diagnostic Studies in Pulmonary TB in HIV/AIDS Patients 
3.7.2. Diagnostic Studies in Pulmonary TB in HIV/AIDS Patients 

3.8. Comprehensive Care of Patients with TB and HIV/AIDS Co-Infection and Therapeutic Considerations 

3.8.1. The System of Comprehensive Care for TB/HIV/AIDS Patients 
3.8.2. Anti-Tuberculosis Treatment Considerations in Patients with TB/HIV/AIDS Co-Infection 
3.8.3. Anti-Tuberculosis Treatment Considerations in Patients with TB/HIV/AIDS Co-Infection 
3.8.4. The Issue of Anti-Tuberculosis and Anti-Retroviral Resistance in These Patients 

Module 4. Multi-Resistance and Vaccines 

4.1. The Silent Epidemic of Antibiotic Resistance 

4.1.1. Globalisation and Resistance 
4.1.2. Change from Susceptible to Resistant of the Microorganisms 

4.2. The Main Genetic Mechanisms of Antimicrobial Resistance 

4.2.1. Describe the Main Mechanisms of Antimicrobial Resistance 
4.2.2. Selective Antimicrobial Pressure on Antimicrobial Resistance 

4.3. Superbugs 

4.3.1. Pneumococcus Resistant to Penicillin and Macrolides 
4.3.2. Multidrug-Resistant Staphylococci 
4.3.3. Resistant Infections in Intensive Care Units (ICUs) 
4.3.4. Resistant Urinary Tract Infections 
4.3.5. Other Multi-Resistant Microorganisms 

4.4. Resistant Viruses 

4.4.1. HIV 
4.4.2. Influenza 
4.4.3. Hepatitis Viruses 

4.5. Multidrug-Resistant Malaria 

4.5.1. Chloroquine Resistance 
4.5.2. Resistance to Other Antimalarials 

4.6. The Main Genetic Studies of Antimicrobial Resistance 

4.6.1. Interpretation of Resistance Studies 

4.7. Global Strategies for Reducing Antimicrobial Resistance 

4.7.1. The Control of Prescribing Antibiotics 
4.7.2. Microbiological Mapping and Clinical Practice Guidelines 

4.8. Overview of Vaccines 

4.8.1. Immunological Basis of Vaccination 
4.8.2. The Process of Vaccination Production 
4.8.3. Quality Control of Vaccines 
4.8.4. Vaccine Safety and Major Adverse Events 
4.8.5. Clinical and Epidemiological Studies for Vaccine Approval 

4.9. The Use of Vaccines 

4.9.1. Vaccine-Preventable Diseases and Vaccination Programmes 
4.9.2. Global Experiences of the Effectiveness of Vaccination Programmes 
4.9.3. Vaccine Candidates for New Diseases

Module 5. Viral Hemorrhagic Fevers and Arboviruses 

5.1. Viral Hemorrhagic Fevers 

5.1.1. Epidemiology 
5.1.2. Classification 
5.1.3. Diagnostic Approach to Viral Hemorrhagic Fevers 
5.1.4. Vaccine Development for New Diseases 
5.1.5. Measures to Control Viral Hemorrhagic Fevers 

5.2. Hemorrhagic Fever Caused by Ebola 

5.2.1. Characteristics and Replicative Cycle of the Virus 
5.2.2. Clinical Picture 
5.2.3. Diagnosis 
5.2.4. Treatment 

5.3. South American Hemorrhagic Fevers 

5.3.1. Characteristics and Replicative Cycle of the Virus 
5.3.2. Clinical Picture 
5.3.3. Diagnosis 
5.3.4. Treatment 

5.4. Arbovirosis 

5.4.1. Epidemiology 
5.4.2. Vector Control 
5.4.3. Other Arboviroses 

5.5. Yellow Fever 

5.5.1. Concept 
5.5.2. Replicative Cycle of the Virus 
5.5.3. Clinical Manifestations 
5.5.4. Diagnosis 
5.5.5. Treatment 

5.6. Dengue 

5.6.1. Concept 
5.6.2. Replicative Cycle of the Virus 
5.6.3. Clinical Manifestations 
5.6.4. Diagnosis 
5.6.5. Treatment 

5.7. Chikungunya 

5.7.1. Concept 
5.7.2. Replicative Cycle of the Virus 
5.7.3. Clinical Manifestations 
5.7.4. Diagnosis 
5.7.5. Treatment 

5.8. Zika 

5.8.1. Concept 
5.8.2. Replicative Cycle of the Virus 
5.8.3. Clinical Manifestations 
5.8.4. Diagnosis 
5.8.5. Treatment 

A unique opportunity to implement the most innovative clinical strategies in infectious diseases in your practice to offer a cutting-edge service, based on the latest scientific and medical developments”